🚀 VC round data is live in beta, check it out!
Aktis Oncology Valuation Multiples
Discover revenue and EBITDA valuation multiples for Aktis Oncology and similar public comparables like Sana Biotechnology, Pharming, SanBio, Keqian Biology and more.
Aktis Oncology Overview
About Aktis Oncology
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. It has one operating segment focused on the research and development of targeted radiopharmaceuticals.
Founded
2020
HQ
Employees
76
Website
Sectors
Financials (LTM)
EV
$880M
Aktis Oncology Financials
Aktis Oncology reported last 12-month revenue of $8M.
In the same LTM period, Aktis Oncology generated $8M in gross profit and had net loss of ($113M).
Aktis Oncology P&L
In the most recent fiscal year, Aktis Oncology reported revenue of $1M and EBITDA of ($50M).
Aktis Oncology expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $8M | XXX | $1M | XXX | XXX | XXX |
| Gross Profit | $8M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | — | XXX | XXX | XXX |
| EBITDA | — | XXX | ($50M) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (3394%) | XXX | XXX | XXX |
| EBIT Margin | (1511%) | XXX | (3500%) | XXX | XXX | XXX |
| Net Profit | ($113M) | XXX | ($44M) | XXX | XXX | XXX |
| Net Margin | (1340%) | XXX | (2958%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Aktis Oncology Stock Performance
Aktis Oncology has current market cap of $1B, and enterprise value of $880M.
Aktis Oncology's stock price is $20.21.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $880M | $1B | 0.0% | XXX | XXX | XXX | $-0.80 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAktis Oncology Valuation Multiples
Aktis Oncology trades at 104.4x EV/Revenue multiple, and (17.4x) EV/EBITDA.
Aktis Oncology Financial Valuation Multiples
As of March 29, 2026, Aktis Oncology has market cap of $1B and EV of $880M.
Equity research analysts estimate Aktis Oncology's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Aktis Oncology has a P/E ratio of (9.9x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1B | XXX | $1B | XXX | XXX | XXX |
| EV (current) | $880M | XXX | $880M | XXX | XXX | XXX |
| EV/Revenue | 104.4x | XXX | 592.0x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | (17.4x) | XXX | XXX | XXX |
| EV/EBIT | (6.9x) | XXX | (16.9x) | XXX | XXX | XXX |
| EV/Gross Profit | 104.4x | XXX | — | XXX | XXX | XXX |
| P/E | (9.9x) | XXX | (25.3x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | 74.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Aktis Oncology Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Aktis Oncology Margins & Growth Rates
Aktis Oncology's revenue in the last 12 month grew by 85%.
Aktis Oncology's revenue per employee in the last FY averaged $0.1M.
Aktis Oncology Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 85% | XXX | 298% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | (3394%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 50% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 760% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1478% | XXX | 2754% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 3600% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Aktis Oncology Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Sana Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| SanBio | XXX | XXX | XXX | XXX | XXX | XXX |
| Keqian Biology | XXX | XXX | XXX | XXX | XXX | XXX |
| Vetoquinol | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Aktis Oncology M&A Activity
Aktis Oncology acquired XXX companies to date.
Last acquisition by Aktis Oncology was on XXXXXXXX, XXXXX. Aktis Oncology acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Aktis Oncology
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAktis Oncology Investment Activity
Aktis Oncology invested in XXX companies to date.
Aktis Oncology made its latest investment on XXXXXXXX, XXXXX. Aktis Oncology invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Aktis Oncology
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Aktis Oncology
| When was Aktis Oncology founded? | Aktis Oncology was founded in 2020. |
| Where is Aktis Oncology headquartered? | Aktis Oncology is headquartered in United States. |
| How many employees does Aktis Oncology have? | As of today, Aktis Oncology has over 76 employees. |
| Is Aktis Oncology publicly listed? | Yes, Aktis Oncology is a public company listed on Nasdaq. |
| What is the stock symbol of Aktis Oncology? | Aktis Oncology trades under AKTS ticker. |
| When did Aktis Oncology go public? | Aktis Oncology went public in 2026. |
| Who are competitors of Aktis Oncology? | Aktis Oncology main competitors are Sana Biotechnology, Pharming, SanBio, Keqian Biology. |
| What is the current market cap of Aktis Oncology? | Aktis Oncology's current market cap is $1B. |
| What is the current revenue of Aktis Oncology? | Aktis Oncology's last 12 months revenue is $8M. |
| What is the current revenue growth of Aktis Oncology? | Aktis Oncology revenue growth (NTM/LTM) is 85%. |
| What is the current EV/Revenue multiple of Aktis Oncology? | Current revenue multiple of Aktis Oncology is 104.4x. |
| Is Aktis Oncology profitable? | No, Aktis Oncology is not profitable. |
| What is the current net income of Aktis Oncology? | Aktis Oncology's last 12 months net income is ($113M). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.